This condition is significant because it is the only known precursor to esophageal adenocarcinoma, a type of cancer that has seen a troubling increase in incidence over the past several decades.

By studying biomarkers known to be involved in gastrointestinal cancers, researchers have developed a biomarker algorithm that, when combined with a noninvasive method to collect esophageal cells for ...

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Intestinal metaplasia does not cause any symptoms by itself, but having it may increase your risk of stomach or esophageal cancer. Genetic factors, diet, and gut bacteria can all contribute to the ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...